Passage Bio Inc. (PASG) Quick Liquidity
The Passage Bio, Inc. (PASG) market price chart demonstrates the price action of an asset whose operations are based on creating gene therapies for pediatric brain pathologies. The orphan status of its developments provides the company with exceptional pricing power and a steady cash flow, which currently stands at 1.23. Meanwhile, the business is implementing energy-saving storage systems and eco-friendly waste disposal, relying on diversified component delivery routes.
Summary analytical data breakdowns for Passage Bio, Inc. (PASG)
The modernization of ultracentrifugation systems and the operation of Passage Bio biomedical sites require significant operating expenses, making liquidity control critical. This metric measures the company's ability to settle short-term debts using cash and accounts receivable, completely excluding illiquid inventory. Analyzing the quick ratio allows an investor to assess the business's real solvency and default risk without accounting for slow-moving assets.